Companies › Fujifilm Pharmaceuticals U.S.A.
1 active drug program in 9 registered trials: 4 Phase 1, 3 Phase 2, 2 Phase 3; Oncology, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Topotecan (FF-10850) DNA topoisomerase I inhibitor | TOP1 | Phase 1 | Advanced Solid Tumors; Retinoblastoma; Pleuropulmonary Blastoma; Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05523869 | Topotecan (FF-10850) | Phase 2 | Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment | Ophthalmology | Feb 2026 |
| NCT04047251 | Topotecan (FF-10850) | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT01783535 | Topotecan (FF-10850) | Phase 2 | Retinoblastoma | Oncology | Feb 2027 |
| NCT04799002 | Topotecan (FF-10850) | Phase 3 | Retinoblastoma | Oncology | Dec 2027 |
| NCT06666712 | Topotecan (FF-10850) | Phase 1 | Brain Tumor, Recurrent | Oncology | Jan 2028 |
| NCT06647953 | Topotecan (FF-10850) | Phase 3 | Pleuropulmonary Blastoma | Oncology | Mar 2029 |
| NCT07334301 | Topotecan (FF-10850) | Phase 1 | Relapsed Neuroblastoma | Oncology | Dec 2030 |
| NCT02813135 | Topotecan (FF-10850) | Phase 1 | Pediatric Cancer | Oncology | Feb 2031 |
| NCT04681417 | Topotecan (FF-10850) | Phase 2 | Retinoblastoma | Oncology | Jan 2035 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.